Received Dec 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 2HJ99 | — |
shingles; (shingles-looking) Rash; itching; bumps; Product Complaint; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 76-year-old male patient who received Herpes zoster (Shingrix) (batch number 2HJ99, expiry date 04-APR-2027) for prophylaxis. This case was associated with a product complaint. On 20-NOV-2025, the patient received the 2nd dose of Shingrix. On an unknown date, less than a month after receiving Shingrix, the patient experienced shingles (Verbatim: shingles), vesicular rash (Verbatim: (shingles-looking) Rash), pruritus (Verbatim: itching), papular rash (Verbatim: bumps) and pharmaceutical product complaint (Verbatim: Product Complaint). The outcome of the shingles was not reported and the outcome of the vesicular rash, pruritus and papular rash were unknown and the outcome of the pharmaceutical product complaint was not applicable. It was unknown if the reporter considered the shingles, vesicular rash, pruritus and papular rash to be related to Shingrix. It was unknown if the company considered the shingles, vesicular rash, pruritus and papular rash to be related to Shingrix. Additional Information: GSK receipt date 18-DEC-2025 The patient complained about having like a shingles-looking rashes everywhere, and some [unintelligible] bumps, looked like shingles and itching. According to reporter, the patient would go to their primary care doctor to confirm if the rash was shingles or not. No further details provided. The reporter consented to follow up.